These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31801012)

  • 1. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis.
    Mui UN; Patel RR; Vangipuram R; Tyring SK
    Skin Therapy Lett; 2019 Nov; 24(6):1-4. PubMed ID: 31801012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tildrakizumab for the treatment of psoriasis.
    Bangert C; Kopp T
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.
    Beck KM; Sanchez IM; Yang EJ; Liao W
    Psoriasis (Auckl); 2018; 8():49-58. PubMed ID: 30214892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
    Crowley JJ; Warren RB; Cather JC
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IL-23 in psoriasis: current perspectives.
    Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
    Psoriasis (Auckl); 2018; 8():1-5. PubMed ID: 29441315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis.
    Näslund-Koch C; Zachariae C; Skov L
    Ther Clin Risk Manag; 2020; 16():903-916. PubMed ID: 33061395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
    Gisondi P; Geat D; Pizzolato M; Girolomoni G
    Curr Opin Pharmacol; 2019 Jun; 46():90-99. PubMed ID: 31212119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review.
    Salimi S; Yamauchi PS; Thakur R; Weinberg JM; Kircik L; Abdelmaksoud A; Wollina U; Lotti T; Sharma A; Grabbe S; Goldust M
    Dermatol Ther; 2020 Jul; 33(4):e13800. PubMed ID: 32530083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab: A Review of Phase II and III Clinical Trials.
    Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
    Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
    Yiu ZZ; Warren RB
    Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis.
    Wytsma J; Woo TE; Parsons L
    Skin Therapy Lett; 2024 May; 29(3):5-8. PubMed ID: 38781953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA; Seemann C; Gerdes S; Mrowietz U
    Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.